Study of the Relationship between Interleukin 17 Levels and Iron Status in Patients with Chronic Myeloid Leukemia

Abstract

Leukemia is one of the most dangerous diseases. It is an abnormal growth of blood-forming stem cells. The bone marrow normally produces many blood cells that do not function normally. The aim of this study was to investigate the relationship between interleukin 17 (IL-17) and iron levels in patients with chronic myeloid leukemia (CML). The study period was from February 25, 2023 to February 5, 2025, and it was conducted at Al-Sadr Medical City in Najaf, Iraq. A blood sample was taken, and iron levels were measured. Serum was also taken from the patients to measure IL-17 levels. The number of patients was 60, and the results were compared with 30 individuals who were considered a control group. The results showed a significant decrease (P < 0.05) in iron levels in blood patients. However, the opposite was true for CML patients, who were significantly lower in IL-17 levels when compared to the control group. The study results indicate a close correlation between iron status and interleukin 17 (IL-17) levels in patients with chronic myelogenous leukemia (CML). Iron metabolism and inflammatory pathways mediated by IL-17 may be indicative of the disease and its health status in CML. These two markers can be used as biomarkers for further study and treatment.